The two dual TLR7/8 agonists, resiquimod and telratolimod (also known as MEDI9197 and 3M-052), have been observed to delay tumour growth when administered intratumourally in models of squamous cell carcinoma [140], melanoma [39], colon adenocarcinoma [29], breast cancer [38], and glioma [141]. The gene discussed is TLR7; the disease is neoplasm.